Results 81 to 90 of about 7,321 (205)
Scientific Reports, 2020 Human immunodeficiency virus (HIV) remains incurable due to latent viral reservoirs established in non-activated CD4 T cells that cannot be eliminated via antiretroviral therapy.
María Rosa López-Huertas +9 more
doaj +1 more source
Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaques
, 2013 Objectives: To investigate the pharmacokinetics (PK) of maraviroc, a CCR5-targeted HIV-1 entry inhibitor, in rhesus macaques following vaginal administration of various maraviroc-loaded aqueous hydroxyethylcellulose (HEC) gels, and to correlate the PK ...
Forbes, Claire J. +6 more
core +1 more source
Breast Cancer Research, 2018 Background Metastatic triple-negative breast cancer (TNBC) is a heterogeneous and incurable disease. Numerous studies have been conducted to seek molecular targets to treat TNBC effectively, but chemotherapy is still the main choice for patients with ...
Kideok Jin +2 more
doaj +1 more source
Maraviroc in the treatment of HIV infection
Drug Design, Development and Therapy, 2008 While a successful HIV vaccine will likely take several more years to become a reality, many anti-retroviral (ARV) drugs are currently available to treat HIV infection, and their efficacious use has improved the quality of life and life expectancy of millions of HIV-infected individuals.
openaire +3 more sources
Maraviroc and raltegravir [PDF]
British Journal of Clinical Pharmacology, 2009 Eline A, Dubois, Adam F, Cohen
openaire +2 more sources
The binding models for maraviroc and TAK-220.
, 2013 The binding models for maraviroc and TAK-220.
Linjie Chen (107280) +7 more
core +1 more source
Microbiology SpectrumThe susceptibility of genetically divergent HIV-1 strains (HIV-1 non-M) from groups O, N, and P to the CCR5 co-receptor antagonist, maraviroc (MVC), was investigated among a large panel of 45 clinical strains, representative of the viral genetic ...
Ségolène Gracias +8 more
doaj +1 more source
Development and application of a simple LC-MS method for the determination of plasma maraviroc concentrations [PDF]
, 2010 Maraviroc is an orally available antagonist of the CCR5 chemokine receptor, which acts as a human immunodeficiency virus type 1 (HIV-1) coreceptor. Binding of maraviroc to this receptor blocks HIV-1 attachment to the coreceptor and prevents HIV-1 from ...
キノシタ, エリ +11 more
core
Effectiveness and cost of treatment with maraviroc in HIV infection
, 2009 Since 1995, life expectancy and quality of life of HIV patients improved significantly due to the use of Highly Active Anti-Retroviral Therapy (HAART), consisting of different combinations of three classes of antiretroviral agents, nucleoside and non ...
Pradelli, Lorenzo, Sacchi, Viola
core +1 more source
, 2020 Background Kidney transplantation in HIV-infected patients is characterized by a concerning high rate of allograft rejections. The etiological mechanisms leading to this increased immunoreactivity are still unknown.
Cappelli, Gianni +13 more
core +1 more source